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Abstract: Amotosalen and ultraviolet A (UVA) photochemical-based pathogen reduction using the Inter-
cept™ Blood System (IBS) is an effective and established technology for platelet and plasma components,
which is adopted in more than 40 countries worldwide. Several reports point towards a reduced platelet
function after Amotosalen/UVA exposure. The study herein was undertaken to identify the mechanisms
responsible for the early impairment of platelet function by the IBS. Twenty-five platelet apheresis units
were collected from healthy volunteers following standard procedures and split into 2 components, 1
untreated and the other treated with Amotosalen/UVA. Platelet impedance aggregation in response to
collagen and thrombin was reduced by 80% and 60%, respectively, in IBS-treated units at day 1 of
storage. Glycoprotein Ib (GpIb) levels were significantly lower in IBS samples and soluble glycocalicin
correspondingly augmented; furthermore, GpIb฀ was significantly more desialylated as shown by(ECL)
binding. The pro-apoptotic Bak protein was significantly increased, as well as the MAPK p38 phospho-
rylation and caspase-3 cleavage. Stored IBS-treated platelets injected into immune-deficient nonobese
diabetic/severe combined immunodeficiency (NOD/SCID) mice showed a faster clearance. We conclude
that the IBS induces platelet p38 activation, GpIb shedding and platelet apoptosis through a caspase-
dependent mechanism, thus reducing platelet function and survival. These mechanisms are of relevance
in transfusion medicine, where the IBS increases patient safety at the expense of platelet function and
survival.
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Introduction
Platelet transfusion is a cornerstone in today’s medicine in general, and more par-
ticularly in hemato-oncology, as illustrated by the 1.3 million platelet units trans-
fused annually in the USA and more than 2.9 million in Europe.1-3 One of the major
challenges in transfusion medicine is the reduction of pathogen transmission by
blood products, in particular for platelet components, since they need storage at
room temperature.4 To circumvent the problem of pathogen contamination of
blood products, pathogen inactivation (PI) technologies have been developed and
routinely implemented in blood transfusion centers worldwide, including the USA,
France and Switzerland.5–7
One such technology, the IBS (Cerus Corporation, Concord, CA, USA), employs
a synthetic psoralen (amotosalen, S-59) and UVA light to induce cross-linking of
DNA and ribonucleic acid (RNA) molecules, thus blocking replication and pathogen
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ABSTRACT
proliferation8 and rendering γ-irradiation for graft-versus-
host disease (GvHD) prophylaxis unnecessary. Several
studies on the efficacy of non-pathogen-reduced versus
IBS-treated platelets reported no cases of transfusion
transmitted infections or transfusion associated GvHD,
together with a reduction of other transfusion reactions.
On the other hand, some reduction in platelet function,
platelet count increments (CI) and corrected count incre-
ment (CCI) have been described.9,10 Although 1 trial
showed an increase in clinically irrelevant World Health
Organization (WHO) grade 2 bleeding,10 other studies did
not find an increase in bleeding, thus confirming the safety
of the IBS technology.9,11–15 However, evaluating platelet
function and survival in vivo is a challenging task due to the
multiple and heterogeneous clinical and pharmacological
factors affecting platelet function in patients. 
Some reports suggest that all pathogen inactivation sys-
tems, including the IBS, aggravate the platelet storage
lesion (PSL) and reduce the platelet function in vitro; the
molecular mechanism behind these observations, howev-
er, is unclear16–18 Abonnenc et al. reported a reduced aggre-
gation response to low-dose TRAP and collagen in IBS-
treated platelets, a finding confirmed in the study by
Picker et al.19,20 The latter also described an increased gly-
colytic flux after pathogen reduction technology (PRT),
with lactate accumulation and increased acidity. Schubert
and Chen reported an increased phosphorylation of sever-
al intracellular kinases and higher caspase activity after
riboflavin and ultraviolet B (UVB) treatment (Mirasol),
which could be reverted by pre-treatment with specific
p38 inhibitors.21,22
The study herein was undertaken in order to test the
hypothesis that the IBS leads to reduced platelet activata-
bility in response to certain agonists (i.e., collagen, throm-
bin and von Willebrand Factor [vWF]), increased platelet
apoptosis and, consequently, enhanced clearance from the
circulation. We therefore compared platelet function and
parameters of apoptosis and clearance of untreated and
IBS-treated human platelets in a large number of in vitro
and in vivo tests in an immune-deficient mouse model
(NOD/SCID). In addition, we analyzed the physiopatho-
logic pathway(s) involved.
Methods
Platelet collection and processing
Platelet apheresis units (AU) were collected from 25 volunteers
at the Regional Blood Transfusion Service of the Swiss Red Cross
of Basel, Switzerland. A table with the AU characteristics is pro-
vided in the Online Supplementary Material. The study was
approved by the Institutional Review Board and each donor pro-
vided written informed consent. Of the 2 AU obtained from each
donor, 1 was kept untreated (non-IBS) and the other treated with
IBS on day 1 after collection according to the standard procedure
(IBS).8 In some cases (n=10), 3 bags were obtained by splitting the
apheresis product from 1 donor: 1 kept untreated (non-IBS), and 2
IBS-treated, of which 1 was injected with a sterile solution of the
p38 inhibitor SB203580 (Sigma-Aldrich; final concentration 20
µM, n=5), or the sialidase inhibitor 2,3-dehydro-2-deoxy-N-
acetylneuraminic acid (DANA, Calbiochem, final concentration
150 µM, n=5) and the other with an equal volume of vehicle
(ethanol). Both were left to incubate overnight before undergoing
the IBS procedure. All AU contained about 1/3 plasma and 2/3 the
platelet additive solution InterSol (Fenwal, Lake Zurich, IL, USA)
and were stored at standard blood banking conditions (22 ±2°C
under gentle agitation).
Adhesion to collagen and vWF under flow
Adhesion in the microfluidic chamber (Fluxion Biosciences, San
Francisco, CA, USA) was performed on citrate, calcein-stained
platelets (4 µM calcein AM, Enzo Life Sciences) at low and high
shear rates (10 dyn/cm2 and 100 dyn/cm2, respectively).23 For
detailed protocol see the Online Supplementary Methods.
In vivo platelet survival in NOD/SCID mouse
Platelets from untreated and IBS-treated AU were incubated
with calcein as described above, then pelleted (340 relative cen-
trifugal force (RCF), 10 min) and resuspended in 0.9% sodium
chloride (NaCl) at 4x109/ml. Eight-week old NOD/SCID male
mice (Charles River, France) were injected intravenously with 100
µl of the platelet suspension.24 Thirty minutes, 2 hours and 5 hours
after injection, a 10 µl blood sample was taken from the tail tip and
mixed with Aster Jandl anticoagulant, centrifuged (125 RCF, 8
min), and 100 µ of the supernatant was immediately analyzed on
a Fortessa LSR II (BD Biosciences).25 The 30 minutes sample was
set as 100%, and the percentages of human platelets in circulation
at 2 and 5 hours were calculated accordingly. Following the final
blood sampling, the animals were euthanized and the spleens
excised and frozen in optimal cutting temperature (O.C.T) medi-
um (Tissue-Tek O.C.T, Sakura Finetek Europe, AJ Alphen aan den
Rijn, The Netherlands). All animal experiments were approved by
and in strict compliance with the local Veterinary Office (animal
licenses 174/2011 and 035/15).
Impedance aggregometry, flow cytometry, ELISA and
Western blotting
Detailed protocol for additional methods (impedance platelet
aggregometry, flow cytometry staining, Western blotting (WB),
glycocalicin enzyme-linked immunosorbent assay (ELISA),
immunofluorescence staining) can be found in the Online
Supplementary Methods.
Statistical analyses
Results are mean ± SEM. Data were analyzed by paired, two-
tailed Student’s t-test, one- or two-way analysis of variance
(ANOVA), followed by Bonferroni post hoc test as appropriate. A
P-value of less than 0.05 was considered significant. All calcula-
tions were performed with GraphPad Prism 5.04 (GraphPad
Software Inc., San Diego, CA, USA).
Results
Amotosalen and UVA photochemical treatment reduces
platelet aggregation
Untreated and IBS-treated samples were analyzed for
aggregation in response to different doses of collagen and
thrombin (Figure 1). At day (d)1 of storage, IBS-treated
platelets showed a maximum collagen-induced aggrega-
tion of 20.5% (5 µg/ml collagen) and 45.2% (10 µg/ml col-
lagen) compared to the non-IBS samples set as 100%
(n=20, P<0.0001; Figure 1A,B). In response to thrombin,
the IBS platelets showed 40.2% of aggregation compared
to the non-IBS samples with a lower dose (0.25 U/ml,
n=20, P<0.0001; Figure 1C), but did not show a significant
difference with a high dose (0.5 U/ml; Figure 1D).
To further evaluate the effects on shear-induced aggre-
gation, platelets were analyzed under low (10 dyn/cm2)
and high (100 dyn/cm2) shear on collagen and human
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vWF-coated channels, respectively. The platelet-covered
area from IBS samples showed a 47% reduction in colla-
gen compared to non-IBS (from 38’561 µm2  to 20’718 µm2,
n=17; Figure 1E), and a 65% reduction on vWF (from 2490
µm2 to 866 µm2, n=17; Figure 1F), which reached a border-
line significance for the area under the curve (AUC) for
collagen (P=0.05; Figure 1G), and was significant for vWF
(P=0.01; Figure 1H).
Amotosalen and UVA photochemical treatment induce
desialylation and cleavage of GpIbα, the release of 
glycocalicin and p38 phosphorylation  
While flow cytometric analyses for Annexin V and PAC-
1 binding and P-selectin exposure showed no significant
difference in IBS samples compared to the untreated con-
trols (Online Supplementary Figure S1A-C), IBS platelets had
a significantly lower expression of the vWF receptor
GpIbα (mean fluorescence intensity (MFI) d1: 2258.9 non-
IBS, 1937.4 IBS, n=20, P=0.01; Figure 2A), which could
contribute to the reduced platelet aggregation on immobi-
lized vWF observed under flow. Consistently, the amount
of the N-terminal fragment of GpIbα (glycocalicin) in the
supernatant was significantly increased by 20% in IBS
samples (Figure 2B). This result was confirmed upon
adjustment of the platelet count per unit (Glycocalicin
Index; Figure 2C). Since the MAPK p38 is directly involved
in TNF-α converting enzyme (TACE) activation and GpIb
shedding, we compared p38 phosphorylation in IBS and
non-IBS platelet lysates and found it to be significantly
increased in the IBS samples (Figure 2D). 
Amotosalen and UV light increases Bak protein level
and induces apoptosis
On account of the key role played by the proteins of the
Bcl-2 family in determining platelet lifespan in vivo,27 we
analyzed the expression of Bak and Bcl-XL in non-IBS and
IBS platelets. The level of the anti-apoptotic protein Bcl-
XL was unchanged (data not shown) but that of the pro-
apoptotic Bak was significantly increased in the 
IBS platelets (Figure 2E). In order to confirm that the
increased level of Bak was inducing platelet apoptosis, we
determined the amount of cleaved caspase-3 in platelet
S. Stivala et al.
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Figure 1. IBS treatment reduces platelet function. Platelet aggregation in response to collagen (A and B) and thrombin (C and D) at days 1, 5 and 7 of storage from
untreated (non-IBS, ◊) versus IBS-treated (■) AU. Lower panel: platelet aggregation under flow on collagen at 10 dyn/cm2 (E) and vWF at 100 dyn/cm2 (F) was also
reduced in IBS samples compared to untreated platelets. Area under the curve (AUC) for the aggregation on collagen reached a borderline significance (G; P=0.05),





















































lysates; as shown in the blot and the relative quantifica-
tion, it was significantly increased in the samples treated
with the IBS as compared to the non-IBS controls (Figure
2F). Immunofluorescence staining of fixed, permeabilized
platelets confirmed an increased Bak intensity for the IBS
platelets (Figure 2G).
IBS treatment reduces platelet survival in vivo
in NOD/SCID mice
Next, we tested the physiological relevance of our find-
ings in vitro on platelet survival in vivo. The AUC for
platelet survival over 5 hours was significantly lower for
the IBS platelets (Figure 3A,B), demonstrating reduced
platelet half-life due to accelerated clearance in vivo upon
transfusion. Taking the first time point (30 min post-injec-
tion) as 100%, 34.4% non-IBS platelets were still circulat-
ing compared to 28.2% IBS at 2 hours (n=15, P>0.05); at 5
hours, they were 26.1% versus 11.5%, respectively
(P=0.05; Figure 3A).
The area of fluorescent platelets in spleens from inject-
ed mice was significantly increased in mice receiving IBS
platelets compared to those injected with untreated
platelets (Figure 3C and corresponding micrographs in the
bottom panel). Under these conditions, we could not
detect platelet clearance in the liver of these mice (data not
shown).
Since it has been reported that GpIbα levels correlate
with platelet survival,28 we analyzed its correlation with
the in vivo survival of non-IBS and IBS platelets and found
a significant positive correlation between GpIb levels and
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Figure 2. IBS induces GpIb shedding from platelets, p38 activation and apoptosis through Bak. MFI of surface GpIbα measured by flow cytometry is significantly
reduced in IBS platelets at day 1 of storage (A) and correspondingly increased in the supernatant when measured by ELISA (B) n=15, P<0.01. (C) Glycocalicin (GC)
concentration from AU supernatant, normalized to the platelet count to give the GC Index, was significantly increased in IBS-treated AU; n=15, P=0.03. Western blot
quantification of phosphorylated p38 (D), (E) Bak expression and (F) caspase-3 cleavage in platelet lysates from untreated or IBS-treated AUs. (G)
Immunofluorescence staining of fixed/permeabilized platelets for Bak (green) and Bcl-XL(red) and relative quantification for Bak. Scale bar = 5µm. *P<0.05,













survival at 2 hours post-injection (r2=0.1993, P=0.028;
Figure 3D). It has been recognized that sialic acid on the
heavily glycosylated GpIbα plays a relevant role in platelet
clearance;26 therefore, we analyzed our samples for desia-
lylation of platelet surface proteins by the fluorescein
isothiocyanate (FITC)-conjugated Erythrina Cristagalli
Lectin (ECL) binding in flow cytometry experiments
(Figure 3E). Erythrina Cristagalli Agglutinin Lectin (ECA)
binds to unsialylated galactose (β1-4) on N-acetyl-glu-
cosamine (GlcNAc) and the ECA-binding level is inversely
proportional to the level of sialylation. Concordant to our
hypothesis, ECA binding was significantly higher in IBS-
treated platelets compared to non-IBS samples, even after
normalization to GpIb levels to account for the increased
receptor shedding in IBS samples (n=6, P=0.006; Figure
3E). In order to confirm that GpIbα desialylation was due
to an increased neuraminidase exposure/release following
Amotosalen/UVA, a specific neuraminidase activity assay
was performed on the supernatants from untreated or IBS-
treated samples. Cleavage of the specific neuraminidase
substrate was significantly higher in supernatants from
samples that underwent the Amotosalen/UVA procedure,
demonstrating a release of neuraminidase from platelets
following the IBS (Figure 3F; P<0.001). Staining of fixed,
non-permeabilized platelets for Neu1 revealed a higher
fluorescence intensity for IBS-treated samples compared
to control ones, while the fluorescence intensity was
equivalent following platelet permabilization to reveal
total (surface and internal) Neu1 (Online Supplementary
Figure S1).
UV light without Amotosalen is sufficient to induce an
increase in apoptotic Bak protein through mRNA 
translation
Platelets don’t have a nucleus but they contain messen-
ger (m)RNA and are capable of translation and protein
S. Stivala et al.
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Figure 3. Platelet clearance in vivo in
NOD/SCID mice is increased in IBS
samples. (A) NOD/SCID mice were
injected intravenously with fluorescent-
ly labeled platelets (untreated ◊,  or
IBS-treated, ■) and the % of circulating
human platelets calculated after 2 and
5 hours; n=10. (B) Area under the
curve (AUC) for the overall platelet sur-
vival of non-IBS versus IBS platelets;
*P=0.02. (C) Spleens from mice inject-
ed with untreated or IBS-treated
platelets were analyzed for the area of
fluorescently-labeled platelets; n=10,
*P=0.018. (D) Correlation analysis of
GpIbα levels and platelet survival 2
hours post-injection in mice. (E)
Desialylation of platelets by FITC-conju-
gated ECA lectin staining and flow
cytometry analysis, normalized to GpIb
levels; n=6, *P<0.05. (F)
Neuraminidase activity was tested in
supernatants from control and IBS
samples and was found to be signifi-
cantly increased after Amotosalen/UVA
treatment; n=18, ****P<0.001.
Bottom panel: representative
microphotograph (4x magnification) of
spleen from mice injected with fluores-
cent non-IBS or IBS platelets (platelet:
green, nuclei: blue). Scale bar = 100
µm. Plotted are mean ±SEM. IBS:
Intercept Blood System; plt: platelet;
ECA: Erythrina Cristagalli Agglutinin;













synthesis.29 We hypothesized, therefore, that the increase
in Bak protein after IBS was due to the translation of BAK
specific mRNA. Immunoprecipitation of eukaryotic initia-
tion factor 4E (eIF4E) followed by quantitative PCR
showed that the relative expression of BAK was increased
significantly 24 hours after irradiation, demonstrating an
increased association of the specific BAK mRNA with
eIF4E (n=4, P=0.01; Figure 4A). This result was confirmed
at the protein level, because WB analysis of the platelet
lysates showed an increased Bak level 24 hours after UV
irradiation compared to non-UV platelets (n=9, P=0.009;
Figure 4B). Blockade of mRNA translation with the pro-
tein synthesis inhibitor cycloheximide (10 µg/ml final con-
centration) was able to block the increase in Bak protein
after UV irradiation (n=3, P=0.01; Figure 4C).
Inhibition of p38 restores GpIb levels but does 
not rescue platelet survival 
Due to the increased p38 phosphorylation observed in
the IBS platelets, we reasoned that inhibition of p38 would
block the adverse effects caused by the Amotosalen/UVA
treatment. However, when injected into NOD/SCID mice,
platelets pre-treated with the p38 inhibitor did not survive
better as compared to untreated platelets, as shown in
Figure 5A. At 2 hours post-injection, 28.5% of SB203580
platelets were circulating compared to 26.4% IBS vehicle-
treated and 41.8% untreated platelets, respectively; at 5
hours, there were 5.08% of the SB203580 samples versus
5.7% of the IBS platelets and 32.2% for the untreated ones,
respectively (n=5, P>0.05; Figure 5A). Analysis of GpIbα
expression on untreated, IBS vehicle and IBS-SB203580
platelets revealed that the receptor cleavage was indeed
blocked in the SB203580 samples, with receptor levels sim-
ilar to the untreated samples (Figure 5B). Loss of sialic acid
from platelet receptors was also prevented by the p38
inhibitor (Figure 5C). Aggregation to collagen and throm-
bin, however, was not different from the vehicle-treated
IBS samples (data not shown). 
Interestingly, we found that levels of the pro-apoptotic
Bak were increased in the SB203580 samples, as shown by
WB analysis of platelet lysate (Online Supplementary Figure
S2A) and by immunofluorescence staining (Online
Supplementary Figure S2B and corresponding microphoto-
graph). Additionally, we found increased levels of cleaved
caspase-3, suggesting that the increment in Bak leads to
platelet apoptosis (Figure 5D).
Exploratory analysis of potential mechanisms with 
the neuraminidase inhibitor DANA 
It has been proposed that desialylation of platelet recep-
tors may in part regulate platelet survival, with the heavily
glycosylated GpIbα being a major contributer.30,31 Since we
observed increased desialylation of platelets after IBS
treatment (Figure 3E), we hypothesized that pre-treatment
of platelets with the neuraminidase inhibitor DANA could
block sialic acid loss and increase platelet survival. As
shown in Figure 6A, 2 hours after injection 31.8% non-IBS
platelets were circulating compared to 20.3% IBS-treated
platelets. Pre-treatment with DANA was able to restore
the circulating platelet value back to 31.4% during the first
2 hours (n=5, P>0.05; Figure 6A). However, this effect was
partly lost at the later time point (5 hours), when circulat-
ing platelets from the DANA sample were 14.2% com-
pared to 22.9% non-IBS and 10.4% IBS-treated, respec-
tively (Figure 6A), possibly as a result of platelet washing
causing removal of the inhibitor before the injection.
GpIbα levels in the DANA samples were similar to those
in IBS samples at all days of storage tested (Figure 6B). We
also analyzed the level of desialylation and found that pre-
incubation with DANA protected platelets from sialic acid
loss, with levels of ECL binding similar to that of the
untreated control at all days tested (Figure 6C). 
Analysis of p38 phosphorylation, Bak expression and
caspase-3 cleavage by WB did not show any significant
difference between the samples (Figure 6D-F) in this series
of experiments, and the limited number of donors (as per
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Figure 4. UV irradiation of platelets induces Bak protein expression through mRNA translation. Platelets were isolated and resuspended in 40% plasma/60%
Intersol and kept either untreated (no UV) or UVA-irradiated (UV). (A) eIF4E was immunoprecipitated 2 or 24 hours after UV irradiation with a specific or a control anti-
body, and Bak quantitative PCR performed on the isolated RNA from the IP. 24 hours after UV irradiation, specific Bak RNA in complex with eIF4E is significantly
increased (n=4, *P=0.01). (B) Bak protein levels normalized to GAPDH are increased 24 hours after UV irradiation, reflecting an increased protein synthesis (n=9,
**P=0.009). (C) Platelets non irradiated or irradiated after pre-treatment with cycloheximide (10 µg/ml) were analyzed for Bak protein expression. Cycloheximide
blocked Bak increase induced by UV (n=3, *P=0.01). qPCR: quantitative polymerase chain reaction.
A B C
ethical approval) did not allow us to increase the number
of samples. In aggregation experiments, the response of
DANA samples to collagen and thrombin was not differ-
ent from that of the IBS samples (data not shown).
Discussion
The study herein analyses in depth the structural and
functional consequences induced by Amotosalen/UVA
treatment using the IBS and the underlying mechanisms.
We provide evidence of diminished platelet function, i.e.,
reduced aggregation and adhesion under flow, and
reduced platelet survival in vivo by increased apoptosis
through Bak upregulation and a caspase-dependent path-
way. We propose mechanisms based on our data (Figure
7) and potential interventions to reverse them. Besides the
significantly reduced platelet response to physiological
agonists in aggregometry, we found a reduced adhesion to
vWF and collagen under flow after IBS treatment from the
first day of storage (Figure 1), implicating a direct and
rapid effect of the IBS on platelet function. This pattern is
explained at the molecular level with a significant loss
(about 20%) of surface GpIbα in IBS-treated platelets, and,
accordingly, the corresponding accumulation of the
cleaved glycocalicin in the supernatant plasma/Intersol
(Figure 2A,B). The reduced aggregation over collagen
could be explained by a reduced ability of platelets to
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Figure 5. Pre-incubation of platelets with SB203580 does not improve platelet survival and exacerbates apoptosis. (A) Platelets from AU untreated, IBS-treated and
pre-treated with the p38 inhibitor SB203580 (final concentration 20 µM) were injected i.v. into NOD/SCID mice, and their survival in the circulation analyzed by flow-
cytometry over 5 hours. The p38 inhibitor did not improve platelet survival compared to untreated platelets. (B) GpIbα expression levels in platelets pre-treated with
SB203580 were comparable to untreated platelets at all days of storage; *P=0.04 IBS vs. non-IBS; **P=0.01 IBS vs. SB203580. (C) When levels of desialylation
were measured by FITC-conjugated ECA lectin binding, SB203580 was able to inhibit desialylation compared to IBS platelets at all days of storage; **P<0.01 non-
IBS vs. IBS. (D) Pre-treatment of platelets with SB203580 induced caspase-3 cleavage; n=5, *P<0.05, **P<0.01, ***P<0.001. IBS: Intercept Blood System; plt:





















respond to external stimuli due to increased Bak-depen-
dent apoptosis, and, additionally, to indirect mechanisms
caused by vWF “bridging” collagen to GpIb. In addition,
the study from Hechler et al.32 found a significant loss of
glycoprotein V (GPV) after Amotosalen/UVA treatment,
and GPV was found to participate in platelet response to
collagen.33 Therefore, we may speculate that IBS-induced
GPV shedding could also be responsible for the reduced
adhesion and aggregation in response to collagen.
Increased loss of GpIb is associated with the typical PSL in
untreated platelets28,34 due to the activation of TACE; our
results support the hypothesis of an accelerated lesion
induced by the IBS which seems to be independent form
the PSL, since it is observed from day 1 of storage. It has
also been shown that cold storage of platelets induces
GpIb desialylation, which primes the receptor for TACE-
dependent shedding.35 Our results extend this observation
to the IBS treatment, since we detected increased platelet
desialylation in the treated samples as compared to the
untreated platelets (Figure 3E) as well as a significantly
increased neuraminidase activity in the supernatant from
IBS samples, suggesting release of the enzyme from
platelets after the PI; these observations suggest that this
is an effect of the IBS (and perhaps of all PI technologies in
general) as well as of storage over time. Interestingly, this
is in line with our earlier structural and functional obser-
vations that deglycosylation of GpIb results in a collapse
of GpIb on the membrane and a loss of platelet-vWF inter-
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Figure 6. Neuraminidase inhibitor DANA partially rescues platelet survival in vivo. (A) control (◊), IBS (■) and DANA (●) platelets were injected in vivo into NOD/SCID
mice and their survival analyzed over 5 hours. DANA-treated platelets were protected from clearance at the early time point (2 hours), at which time the clearance
matched the non-IBS controls, but not at the later stage (5 hours). (B) GpIbα cleavage in DANA-treated samples was comparable to IBS samples at all days of storage;
*P=0.03 IBS/DANA vs. non-IBS. (C) Desialylation was abrogated in the presence of DANA up to 7 days of storage; *P=0.03 IBS vs. non-IBS. (D) Immunofluorescence
staining and (E) WB analysis of Bak and cleaved caspase-3 (F) revealed no difference between non-IBS, IBS and DANA samples; n=5, P>0.05. IBS: Intercept Blood






















action.36 Thus, a dual effect of the IBS on GpIb (cleavage
and desialylation) may lead to platelet clearance. Indeed,
in vivo, we found a significant correlation of the increased
clearance of IBS platelets in the spleen of NOD/SCID
mice; platelet clearance correlated with GpIb levels, con-
firming the important role of this receptor for platelet sur-
vival, as also demonstrated by other groups.35,37,38 The sial-
idase inhibitor DANA seems to reduce, in part, the loss
and clearance of IBS-treated platelets in vivo in our platelet
survival model in NOD-SCID mice (Figure 5A-C), albeit
only at the early time point. DANA pre-treated samples
did not show an increase in Bak or in cleaved caspase-3
observed after IBS treatment. Interestingly, and perhaps
surprisingly, we could not detect platelet clearance in the
liver of these mice, in spite of the important role played by
the Ashwell-Morell receptor on hepatocytes in the
removal of desialylated platelets26,39 (data not shown); how-
ever, the extensive shedding of GpIbα after
Amotosalen/UVA could be responsible for blocking the
recognition and hepatic clearance of desialylated platelets. 
At the intracellular level, we found that the IBS was
linked to an increased phosphorylation of the signalling
molecule p38 (Figure 2D), in agreement with previous
reports of storage of untreated platelets.21,34 Interestingly,
p38 is a known TACE activator,40 thus its increased phos-
phorylation is directly linked to the increment in GpIb
cleavage observed in IBS platelets in this study (Figure
2A,B). Pre-incubation with a specific p38 inhibitor
(SB203580) reduced GpIb shedding and desialylation upon
IBS treatment but did not improve platelet survival in mice
(Figure 5A,B), suggesting that restoring GpIb levels is not
sufficient to reduce platelet removal and that other mech-
anisms play a role in the accelerated clearance of IBS
platelets, possibly through the induction of apoptosis,
which was worsened by the p38 inhibitor as shown by
cleaved caspase-3 levels (Figure 5D).
Other than cleavage, the induction of apoptosis could
represent an important mechanism of platelet clearance, as
has been shown for the riboflavin/UV light-based (Mirasol)
PI.17,22 Expression of the pro-apoptotic protein Bak and
cleavage of caspase-3 were significantly increased in IBS
samples compared to non-IBS, confirming induction of
platelet apoptosis as a mechanism of the reduced platelet
function, and accelerated clearance after PI (Figure 2E-G). In
contrast to previous studies,19,32,41 we did not detect an
increased activation of the fibrinogen receptor GpIIbIIIa
(Online Supplementary Figure S1C); this could be partly
explained by the different protocol used for platelet collec-
tion, which was shown to affect platelet activation.42,43
Schripchenko et al. recently reported that p38 or siali-
dase inhibition could not block PSL caused by 4°C storage,
in agreement with our results.44 However, this is in con-
trast to the results of other groups, which show ameliora-
tion of platelet function after p38 inhibition or GpIb shed-
ding blockade during storage.21,34,45 The reason for these
contrasting results remains unclear at this point. An
intriguing hypothesis is that p38 activation in response to
the stress associated with PI may have a protective role,
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Figure 7. Schematic image represent-
ing the mechanisms found in our
study. (1) IBS leads to phosphorylation
of p38 (2), which in turn causes TNF-α
converting enzyme (TACE) activation
and GpIb shedding (3). The latter is
also up-regulated by the release of
neuraminidase from intracellular
stores, which cleaves sialic acid
residues on GpIbα, priming the recep-
tor for cleavage. IBS also induces (like-
ly by UV) upregulation of the pro-apop-
totic Bak (4), which results in the
induction of apoptosis through a cas-
pase-dependent pathway. Both
processes lead to a reduced response
of platelets to agonists and an acceler-
ated clearance in vivo. GC: glycocalicin.
which leads to an increased apoptosis when inhibited, as
reported by Rukoyatkina et al.46 An interesting observation
of our study is that the IBS induces expression of the pro-
apoptotic protein Bak, and this is replicated when freshly
isolated platelets are irradiated with UVA without the
addition of Amotosalen (Figure 3E,F and Figure 4B). We
were also able to show that this occurs through an
increased mRNA translation following its association with
the protein eIF4E, considering that the protein synthesis
inhibitor cycloheximide was able to block the increase in
Bak after UV (Figure 4A,C). Since platelets contain mRNA
and all the necessary machinery to enable them to trans-
late into proteins,29,47 our results suggest that PI might trig-
ger translation of specific mRNA inducing apoptosis, sim-
ilar to the way in which it alters mRNA and microRNA
expression.18,48 The development of PI represents a major
cornerstone in transfusion medicine by reducing the risk
of transfusion transmitted diseases in patients receiving
blood products. The downside of this technology is the
observation that PI exacerbates the PSL and has an impact
on platelet function, although one study reported no
change in platelet aggregation when washed platelets
were used, the significance of which is not clear since the
number of platelet concentrates analyzed was
low.7,17,22,32,49,50 The study herein clearly demonstrates that
platelet treatment with Amotosalen/UVA causes an alter-
ation of platelet function. However, we also observed a
detrimental effect with UVA treatment alone, and a nega-
tive impact on platelet function has  been reported for γ-
irradiation.51 Therefore, whether the IBS has a different or
greater effect on platelets remains unclear. Importantly,
we provided a mechanistic insight into the pathways
involved in the negative effects of the Amotosalen/UVA
treatment on platelets. 
Although a large number of clinical studies did not
demonstrate an inferior clinical efficacy of IBS-treated
platelets, further research on the clinical outcomes of IBS-
treated platelet transfusion, focusing on bleeding, are nec-
essary. The implementation of the IBS in more than 40
countries worldwide shows the necessity of technologies
capable of reducing the risk associated with blood prod-
ucts transfusion, in spite of the alterations in platelet func-
tion caused by the procedure. Nevertheless, our observa-
tions indicate the importance of developing strategies that
can be implemented to PI methods (such as new platelet
additive solutions) in order to preserve platelet function
and thus provide patients with safer,  qualitatively optimal
transfusion products.52-54
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